Thymidylate Synthase Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Thymidylate synthase inhibitors inhibit the enzyme thymidylate synthase which prevents the methylation of C5 of deoxyuridine monophosphate (dUMP) thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP). The effect is shown by the promotion of cell death as cells would not be able to properly undergo DNA synthesis if they are lacking dTMP which is a necessary precursor to dTTP. Thymidylate synthase inhibitors are generally indicated for breast cancer, lung cancer, gastric cancer, colorectal cancer, acute lymphocytic leukemia, thoracic cancer, and others. It is also indicated for rheumatoid arthritis and psoriatic arthritis. Roche, Eli Lilly, Taiho Pharmaceutical, Medac Pharma, AstraZeneca, Merck, and Eagle Pharmaceutical are some of the pharmaceutical companies with thymidylate synthase inhibitors in the market. Moreover, some of the companies have thymidylate synthase inhibitors in phase-I/II of clinical trials for cancer indications.

Key Market Developments:

• In Dec 2022, US FDA approved Eagle Pharmaceuticals’ Pemetrexed for non-small cell lung cancer in the USA.
• In Mar 2023, Medac Pharma launched (Metoject) Methotrexate subcutaneous auto-injection for juvenile rheumatoid arthritis, psoriasis, and psoriatic arthritis in Denmark, Portugal, Norway, Germany, Finland, Greece, France, Poland, Spain, Czech Republic, UK, Austria, Netherlands, and Sweden.
• In Apr 2023, Isofol Medical and Oncosyne AS entered into a research collaboration to evaluate the effect of drug candidate Arfolitixorin in different doses combined with the cancer drug 5-FU.

Approved Thymidylate synthase inhibitors:

• LEUCOVORIN (5-Fluorouracil)
• XELODA (Capecitabine)
• ALIMTA (Pemetrexed)
• TEYSUNO (Gimeracil/Oteracil/Tegafur)
• CARAC (Fluorouracil topical)
• TOMUDEX (Raltitrexed)
• FUSILEV (Levoleucovorin calcium)
• FOLOTYN (Pralatrexate)
• UFTORAL (Tegafur/Uracil)
• PEMFEXY (Pemetrexed)

Drugs under the Pipeline for Thymidylate synthase inhibitors:

• Modufolin (Arfolitixorin)
• Orzel (UFT + Leucovorin)
• TG6002
• Fosifloxuridine Nafalbenamide (NUC-3373)
• Furtulon (Doxifluridine)
• LX-101
• CX1106
• TBI 302
• TMV-018
• Thymitaq (Nolatrexed)
• Idetrexed (CT900)
• Irinotecan/Floxuridine (LY01616)
• Vodobatinib (SCO - 088)

Clinical Activity and Developments of Thymidylate synthase inhibitors:

Currently, there are about 10 drug molecules in the market for thymidylate synthase inhibitors with more than 15 drug molecules in clinical trials.

• In Nov 2022, Roche in collaboration with Novartis, Sanofi, Breast International Group, and Agendia completed a phase-III trial for breast cancer in European Union for the drug molecule Capecitabine.
• In Jan 2023, Eli Lilly and Company and Saint John’s Cancer Institute completed a phase-I clinical trial for Chordoma in the USA for IV administration of Pemetrexed.